A newly identified mechanism lends credence to the idea that MS may be treatable by targeting EBV-infected B-cells, a study found.
Detailed price information for Biovaxys Technology Corp (BIOV-CN) from The Globe and Mail including charting and trades.
A deep dive into the Fc–FcR axis as a therapeutic anchor in autoimmune disease, examining immune signaling and drug ...
Researchers at VCU Massey Comprehensive Cancer Center and the VCU Institute of Molecular Medicine (VIMM) were recently ...
Indian Defence Review on MSN
Doctors Confirm: Eating This Popular Korean Side Dish Daily Could Boost Your Immune System
A familiar Korean side dish is gaining scientific traction for its ability to subtly fine-tune the body’s immune system.
A new comprehensive review from researchers at the Icahn School of Medicine at Mount Sinai details how decades of cancer ...
Cancer evolves through layers of change: mutations in DNA, shifts in gene regulation, altered cell behaviour, and dynamic ...
We report a rare case of acute neurological Behçet’s disease (neuro-BD) diagnosed concurrently with systemic Behçet’s disease ...
Phase 2 clinical trial will evaluate the safety, translational biology, and exploratory clinical efficacy of VYD2311 in people with Long COVID or COVID vaccine injuryParticipants to include people wit ...
PHILADELPHIA, PA & SAN FRANCISCO, CA — Dispatch Bio said the U.S. Food and Drug Administration has cleared its ...
CARVYKTI ® is the first and only BCMA-targeted CAR-T cell therapy approved for the treatment of patients with multiple myeloma who have had at least one prior line of therapy. Globally, CARVYKTI ® is ...
T-cell engagers are antibody-based therapeutics that can reprogram T cells for antigen-specific elimination of target cells. The modality has remained a big draw for Big Pharma, with Eli Lilly penning ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results